

Souhrn plánu řízení rizik podle § 99 odst. 8 písm. a) zákona č. 378/2007 Sb., o léčivech a o změnách některých souvisejících zákonů (zákon o léčivech), ve znění pozdějších předpisů (1)

Avortaxo 5 mg, 10 mg, 15 mg, 20 mg potahované tablety

Administrativní informace:

Léčivá látka/látky	vortioxetin
Léková forma/formy	potahovaná tableta
Síla/síly	5 mg, 10 mg, 15 mg, 20 mg
Držitel rozhodnutí o registraci	Vipharm S.A.
Registrační číslo/čísla	30/271/24-C, 30/272/24-C, 30/273/24-C, 30/274/24-C
Verze a datum plánu řízení rizik	1.0, 16.06.2025

Následující výňatek z plánu řízení rizik (RMP) výše uvedeného léčivého přípravku/léčivých přípravků je souhrnem podstatných informací uvedených ve zmíněném RMP. RMP popisuje opatření, která mají být přijata, aby bylo zajištěno, že tento léčivý přípravek/tyto léčivé přípravky budou používány co nejbezpečněji. Souhrn RMP je potřeba číst spolu se schváleným souhrnem údajů o přípravku/přípravcích a příbalovou informací.

Tento souhrn RMP připravil Státní ústav pro kontrolu léčiv za účelem splnění své zákonné povinnosti týkající se transparentnosti vůči veřejnosti.

1) [Zákon č. 378/2007 Sb., o léčivech, ve znění pozdějších předpisů](#)

Summary of risk management plan for Avortaxo, 5 mg, 10 mg, 15 mg, 20 mg, film-coated tablets (vortioxetine)

This is a summary of the risk management plan (RMP) for Avortaxo, 5 mg, 10 mg, 15 mg, 20 mg, film-coated tablets. The RMP details important risks of Avortaxo, how these risks can be minimised, and how more information will be obtained about Avortaxo's risks and uncertainties (missing information).

Avortaxo's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Avortaxo should be used.

Important new concerns or changes to the current ones will be included in updates of Avortaxo's RMP.

The medicine and what it is used for

Avortaxo is authorised for the treatment of major depressive episodes in adults.

It contains vortioxetine as the active substance and it is given by oral route of administration.

I. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Avortaxo, together with measures to minimise such risks and the proposed studies for learning more about Avortaxo's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without a prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of Avortaxo is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Avortaxo are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks

can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Avortaxo. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	Serotonin syndrome
Important potential risks	none
Missing information	Off-label paediatric use

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Avortaxo.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Avortaxo.